Clinical trial Recruiting at 2 sites Phase 4 Interventional Ages 60 and up

Combining exercise and medication to reduce bone loss during weight loss in older adults

Official title: The Bone, Exercise, Alendronate, and Caloric Restriction Trial

Run by Wake Forest University Health Sciences · NCT05764733 · Data updated 2026-11-12

This study is testing if combining exercise and medication can help older adults lose weight without losing bone strength.

Quick facts

PhasePhase 4
Study typeInterventional
Ages60 Years and up
SexAll
Enrollment900 (estimated)
SponsorWake Forest University Health Sciences
Academic / other
Drugs / interventionsdenosumab
Locations2 sites (Aurora, Colorado and 1 other locations)
StatusRecruiting
StartedJune 8, 2023
Main results expectedJanuary 2028
Study endsJanuary 2028
Registry record updatedJune 9, 2026
Trial IDNCT05764733 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are community-dwelling older adults with low bone density and a BMI of 25 or higher who are looking to lose weight.

Probably not a fit

Patients who are unable to walk independently or have severe musculoskeletal disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research aims to identify effective strategies to minimize bone loss in older adults undergoing weight loss. Participants will engage in a 12-month intervention that includes resistance training, bone-loading exercises, and bisphosphonate treatment, while all receiving a group-mediated dietary weight loss program. The study will assess changes in bone mineral density and quality through various imaging techniques over a period of up to two years. Participants will be randomized into one of four groups to evaluate the independent and combined effects of the interventions.

Why it matters

Potential benefit: If successful, this study could help older adults maintain bone health while losing weight, reducing the risk of fractures and osteoporosis.

How similar studies have gone: Other studies have shown promising results with similar interventions aimed at preserving bone health during weight loss, indicating potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Community-dwelling
* BMI\>30 kg/m\^2 or BMI 25.0 to \<30 kg/m\^2 plus one risk factor
* Currently receiving routine (annual) dental care
* Pre-existing low bone mass (T-score ≤-1.1 to \>-2.5 at the hip, femoral neck, or lumbar spine (L1-L4))

Exclusion Criteria:

* Weight greater than 450 lbs (DXA limit)
* Resides with someone who is currently participating in BEACON
* Dependent on quad cane or walker; inability to walk independently
* History of mild cognitive impairment or dementia or evidence of cognitive impairment ((score \<20) on Montreal Cognitive Assessment (MoCA))
* Excessive alcohol use (\>21 drinks/week) in the past month; any non-cannabis illicit drug use
* Weight change ≥5% in past 3 months
* Regular participation (\>60 mins per day on \> 3 days/week) in structured strength training program for \>6 months
* Severe arthritis, fracture, chronic injury, or other musculoskeletal disorder that prevents safe exercise participation; joint replacement or other orthopedic surgery in past 6 months or planned in next 12 months; invasive dental procedure (i.e. extraction/implant) in past 6 month or planned in next 12 months
* Osteoporosis (any of the following): Self-reported and on prescription osteoporosis medication; self-reported prior spine, hip, wrist, or shoulder fracture after age 40 (except when caused by trauma or fall from height), including atypical femoral fractures (AFF); or ≥20% for major osteoporotic fracture at screening
* Uncontrolled hypertension (systolic \>180 OR diastolic \>110 mmHg) upon repeated assessments (up to 3 times)
* Uncontrolled type 2 diabetes (HbA1c \>8%); dialysis or abnormal kidney function (eGFR \<45 mL/min/1.73 m2); liver disease or abnormal liver function (ALT levels 2 times above normal); anemia (Hb\<LLN); calcium above or below normal limit; uncontrolled thyroid disease (hypo/hyper) or requiring recent (past 3 months) adjustments in thyroid hormone supplementation or thyroid-stimulating hormone \<LLN or \>10 mIU/ml; vitamin D deficiency (\<20 ng/mL).
* Stroke, heart attack, heart failure hospitalization, or revascularization procedure within the past 6 months; chronic respiratory disease requiring oxygen; PAD diagnosis within the last 12 months; uncontrolled angina; progressive neurological disease; malabsorption disorder; any disease suggesting a life-expectancy \<3 years; bilateral hip replacement; past or planned bariatric surgery; cancer requiring initial treatment within the last 12 months (except non-melanoma skin cancers); major vision or hearing loss; unstable gastric reflux; esophageal stricture, achalasia, or Barrett's esophagus
* Daily use of growth hormones, weight loss medications, oral steroids, or diabetes prescriptions (such as insulin, thiazolidinediones, or canagliflozin); known allergy to bisphosphonates; prior use of oral bisphosphonates for \>3 months within the past 3 years; zoledronic acid within the past 5 years; denosumab use within the past year; anabolic agents for \>3 months in the last year; current use of biotin or strontium; history of 3+ years of antiresorptive therapy
* Unable/unwilling to: provide own transportation to study visits, commit to study protocol (including random assignment), or adhere to data collection visits
* Current participation in another intervention research study; planned out-of-town trip greater than 1 month at a time during the first 6 months of the study; unwilling to provide informed consent, including consent to access personal electronic health records; judged unsuitable for the trial for any reason by research team

Where it's running

  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado, United States
    Recruiting
  • Atrium Health Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina, United States
    Recruiting

Study contacts

  • Principal investigator: Kristen Beavers, PhD — Wake Forest University Health Sciences
  • Study coordinator: Christa Todoroff Calderone, M.S.
  • Email: todorocm@wfu.edu
  • Phone: 336-758-5019

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.